Business Context and Reporting Period
Company: Bioanalytical Systems, Inc. (Note: The input metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2002
Business Overview: The Company provides contract development services and research equipment to pharmaceutical, medical device, and biotechnology companies. Operations are divided into two segments: Analytical Services (preclinical safety, bioanalysis, formulation) and Analytical Products (robotic blood sampling, chromatography, and electrochemistry instruments). The Company serves clients globally, with approximately 24% of revenue generated outside the United States.
Key Financial Metrics
Revenue by Segment (Fiscal Year 2002):
- Services Unit: $16,140,000
- Products Unit: $10,373,000
Research and Development: $1,521,000 (Fiscal Year 2002)
Debt and Liquidity:
- Credit Facility: A Credit Agreement with The Provident Bank (dated Oct 29, 2002) includes a loan of $6,000,000. Interest rates are variable (Prime + 0-125 bps or LIBOR + 200-350 bps) based on leverage ratios.
- Acquisition Financing: Issued $2,250,000 in promissory notes (10% interest, maturing Oct 1, 2007) for the acquisition of LC Resources, Inc.
- Intercompany Note: Extended a Secured Convertible Revolving Note of up to $925,000 to PharmaKinetics Laboratories, Inc. (PKLB) at 8% interest, due May 1, 2003.
Market Data (as of Dec 31, 2002):
- Shares Outstanding: 4,590,045
- Market Value of Non-Affiliate Equity: $12,530,823
Note: The filing text incorporates the Consolidated Statements of Operations, Balance Sheets, and Cash Flows by reference to the Annual Report. Specific values for Net Income, Total Assets, Total Liabilities, and Operating Cash Flow are not explicitly stated in the provided text.
Material Changes and Acquisitions
Acquisitions and Mergers:
- PharmaKinetics Laboratories, Inc. (PKLB): Entered into a Merger Agreement (amended Nov 2002) to acquire PKLB. The transaction is expected to close prior to March 31, 2003. Consideration includes cash, convertible notes, and stock. The Company has provided $350,000 in working capital loans and a $925,000 revolving note to PKLB.
- LC Resources, Inc. (LCR): Acquired on December 13, 2002, for $2.5 million ($125,000 cash + $2.25 million in notes). This acquisition expands the Company's capabilities.
Customer Concentration:
- Pfizer: Accounted for 19.0% of total revenue in 2002 (18.9% in 2001, 21.0% in 2000).
- Pharmacia: Accounted for 9.3% of total revenue in 2002 (11.7% in 2001, 12.2% in 2000).
- Merger Impact: Pfizer and Pharmacia announced a merger; the Company notes no current impact on the relationship, but acknowledges the risk of increased concentration.
Outlook, Risks, and Management Commentary
Management Commentary:
- Industry Trends: Management anticipates continued growth in outsourced R&D services due to cost containment pressures, patent expirations, and the need for accelerated drug development.
- Strategy: Focus on key account development among the top 200 global pharmaceutical companies and expanding the distributor network internationally.
- Backlog: The Company does not disclose backlog because service contracts are terminable by clients with 30 days' notice.
Risks and Contingencies:
- Customer Dependence: Significant reliance on a few large clients (e.g., Pfizer/Pharmacia). Loss of a major client could materially affect results.
- Regulatory Compliance: Operations are subject to strict FDA GLP/GMP guidelines, USDA animal welfare regulations, and DEA controlled substance laws. Non-compliance could result in data disqualification or operational shutdowns.
- Market Risk: Exposure to interest rate changes (variable rate debt) and foreign currency fluctuations. Management estimates a 10% adverse change in either would not materially affect operating results.
- Acquisition Risks: The PKLB merger is subject to shareholder approval and regulatory conditions. Failure to close could impact strategic growth plans.
Investor Verification Checklist
- Financial Statements: Verify the full Consolidated Statements of Operations and Cash Flows in the referenced 2002 Annual Report to confirm Net Income, EBITDA, and cash flow positions, as these are not detailed in the 10-K text provided.
- PKLB Merger Status: Confirm the closing status of the PharmaKinetics Laboratories, Inc. merger and the final consideration paid, as the filing indicates it was pending as of the report date.
- Debt Covenants: Review the specific financial covenants in the Credit Agreement with The Provident Bank and Union Planters Bank to assess liquidity constraints.
- Customer Concentration: Monitor the post-merger relationship with the combined Pfizer/Pharmacia entity to assess revenue stability.
- Regulatory Audits: Verify the status of any recent FDA or USDA audits to ensure no material compliance issues exist that could disrupt operations.